Haemonetics (HAE) Scheduled to Post Earnings on Thursday

Haemonetics (NYSE:HAE) is scheduled to release its earnings data before the market opens on Thursday, May 9th. Analysts expect Haemonetics to post earnings of $0.88 per share for the quarter. Haemonetics has set its FY 2024 guidance at 3.900-4.000 EPS and its FY24 guidance at $3.90-4.00 EPS.Persons that wish to listen to the company’s earnings conference call can do so using this link.

Haemonetics (NYSE:HAE) last posted its earnings results on Thursday, February 8th. The medical instruments supplier reported $1.04 EPS for the quarter, beating analysts’ consensus estimates of $0.94 by $0.10. Haemonetics had a net margin of 9.97% and a return on equity of 22.37%. The firm had revenue of $336.20 million for the quarter, compared to the consensus estimate of $320.84 million. During the same period last year, the firm posted $0.85 EPS. The company’s revenue was up 10.1% on a year-over-year basis. On average, analysts expect Haemonetics to post $4 EPS for the current fiscal year and $4 EPS for the next fiscal year.

Haemonetics Stock Performance

NYSE HAE opened at $95.35 on Tuesday. The company has a fifty day moving average of $82.81 and a two-hundred day moving average of $82.69. The company has a market capitalization of $4.84 billion, a PE ratio of 38.76, a P/E/G ratio of 2.23 and a beta of 0.34. Haemonetics has a 1 year low of $70.74 and a 1 year high of $96.25. The company has a debt-to-equity ratio of 0.91, a current ratio of 2.92 and a quick ratio of 1.76.

Wall Street Analyst Weigh In

HAE has been the subject of a number of research reports. Barrington Research reaffirmed an “outperform” rating and issued a $105.00 target price on shares of Haemonetics in a report on Friday, April 12th. StockNews.com downgraded Haemonetics from a “buy” rating to a “hold” rating in a research note on Friday, March 22nd. Finally, TheStreet downgraded Haemonetics from a “b-” rating to a “c+” rating in a research note on Thursday, February 29th.

About Haemonetics

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and intravenous solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system, and Donor360.